Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.

Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ.

Mol Cancer Ther. 2014 Feb;13(2):528-39. doi: 10.1158/1535-7163.MCT-13-0646. Epub 2013 Oct 29.

2.

A common gene variant in PLS3 predicts colon cancer recurrence in women.

Szkandera J, Winder T, Stotz M, Weissmueller M, Langsenlehner T, Pichler M, Samonigg H, Renner W, Gerger A, Absenger G.

Tumour Biol. 2013 Aug;34(4):2183-8. doi: 10.1007/s13277-013-0754-7. Epub 2013 Apr 3.

PMID:
23549633
3.

Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.

Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, Rodríguez-Salas N, Burgos E, Ramos D, Calatrava A, Andrada E, Díaz-López E, Sánchez A, Madero R, Cejas P, Feliu J.

Mol Cancer Ther. 2014 Sep;13(9):2226-37. doi: 10.1158/1535-7163.MCT-13-1109. Epub 2014 Jun 30.

4.

Common cancer stem cell gene variants predict colon cancer recurrence.

Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ.

Clin Cancer Res. 2011 Nov 1;17(21):6934-43. doi: 10.1158/1078-0432.CCR-11-1180. Epub 2011 Sep 14.

5.

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.

Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ.

Pharmacogenomics J. 2015 Jun;15(3):226-34. doi: 10.1038/tpj.2014.66. Epub 2014 Dec 9.

PMID:
25487679
6.

Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.

Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ.

Ann Oncol. 2008 Oct;19(10):1734-41. doi: 10.1093/annonc/mdn368. Epub 2008 Jun 11.

7.

The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.

Absenger G, Benhaim L, Szkandera J, Zhang W, Yang D, Labonte MJ, Pichler M, Stotz M, Samonigg H, Renner W, Gerger A, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):130-4. doi: 10.1038/tpj.2013.15. Epub 2013 Apr 9.

PMID:
23567490
8.

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.

Lou YT, Chen CW, Fan YC, Chang WC, Lu CY, Wu IC, Hsu WH, Huang CW, Wang JY.

PLoS One. 2015 Apr 28;10(4):e0123973. doi: 10.1371/journal.pone.0123973. eCollection 2014.

9.

Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.

Giráldez MD, Lozano JJ, Cuatrecasas M, Alonso-Espinaco V, Maurel J, Mármol M, Hörndler C, Ortego J, Alonso V, Escudero P, Ramírez G, Petry C, Lasalvia L, Bohmann K, Wirtz R, Mira A, Castells A.

Int J Cancer. 2013 Mar 1;132(5):1090-7. doi: 10.1002/ijc.27747. Epub 2012 Aug 12.

10.

Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.

Stotz M, Herzog SA, Pichler M, Smolle M, Riedl J, Rossmann C, Bezan A, Stöger H, Renner W, Berghold A, Gerger A.

Anticancer Res. 2017 Apr;37(4):2011-2018.

PMID:
28373475
11.

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.

Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):135-41. doi: 10.1038/tpj.2013.21. Epub 2013 Jun 11.

PMID:
23752739
12.

LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.

Szkandera J, Herzog S, Pichler M, Stiegelbauer V, Stotz M, Schaberl-Moser R, Samonigg H, Asslaber M, Lax S, Leitner G, Renner W, Lenz HJ, Berghold A, Gerger A.

Pharmacogenomics J. 2015 Oct;15(5):391-6. doi: 10.1038/tpj.2015.2. Epub 2015 Feb 10.

13.

Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis.

Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, Nishida N, Kogo R, Sudo T, Tanaka F, Shibata K, Toh H, Sato T, Barnard GF, Fukagawa T, Yamamoto S, Nakanishi H, Sasaki S, Miyano S, Watanabe T, Kuwano H, Mimori K, Pantel K, Mori M.

Cancer Res. 2013 Apr 1;73(7):2059-69. doi: 10.1158/0008-5472.CAN-12-0326. Epub 2013 Feb 1.

14.

Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.

Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X.

Cancer. 2012 Dec 15;118(24):6188-98. doi: 10.1002/cncr.27653. Epub 2012 Jun 6.

15.

Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.

Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhanim L, Kahn M, Lenz F, Lenz C, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):142-50. doi: 10.1038/tpj.2013.20. Epub 2013 Jul 2.

PMID:
23817222
16.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.

J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.

PMID:
26527776
17.

Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.

Yun HR, Kim HC, Yun SH, Lee WY.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2466-71. doi: 10.5754/hge10260.

PMID:
23169179
18.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
19.

Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.

Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, O'Connor-McCourt M, Wang E.

JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413.

PMID:
26502222
20.

Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR.

N Engl J Med. 2001 Apr 19;344(16):1196-206.

Supplemental Content

Support Center